Automate Your Wheel Strategy on DOCS
With Tiblio's Option Bot, you can configure your own wheel strategy including DOCS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DOCS
- Rev/Share 3.1366
- Book/Share 5.4558
- PB 13.4079
- Debt/Equity 0.0115
- CurrentRatio 6.4675
- ROIC 0.1929
- MktCap 13710067063.0
- FreeCF/Share 1.5285
- PFCF 47.7144
- PE 58.4832
- Debt/Assets 0.0098
- DivYield 0
- ROE 0.2294
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | DOCS | Goldman | Neutral | Sell | -- | $64 | Oct. 1, 2025 |
| Upgrade | DOCS | Evercore ISI | In-line | Outperform | -- | $70 | July 9, 2025 |
| Upgrade | DOCS | BTIG Research | Neutral | Buy | -- | $80 | June 2, 2025 |
| Upgrade | DOCS | Piper Sandler | Neutral | Overweight | $31 | $78 | Feb. 7, 2025 |
| Upgrade | DOCS | Leerink Partners | Market Perform | Outperform | $60 | $90 | Feb. 7, 2025 |
| Initiation | DOCS | Stephens | -- | Equal Weight | -- | $55 | Dec. 20, 2024 |
| Initiation | DOCS | Mizuho | -- | Neutral | -- | $55 | Dec. 4, 2024 |
| Upgrade | DOCS | Barclays | Equal Weight | Overweight | $35 | $52 | Oct. 15, 2024 |
News
Is Doximity (DOCS) a Solid Growth Stock? 3 Reasons to Think "Yes"
Published: February 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Doximity (DOCS) possesses solid growth attributes, which could help it handily outperform the market.
Read More
5 Top-Ranked Stocks Poised for an Earnings Beat
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Top-ranked stocks Tenet Healthcare (THC), Fortinet (FTNT), Lyft (LYFT), Garmin (GRMN) and Doximity (DOCS) are likely to beat on the bottom line in their upcoming releases.
Read More
Doximity: Rating Downgrade As Near-Term Upside Is Priced In
Published: February 14, 2025 by: Seeking Alpha
Sentiment: Positive
I downgraded Doximity from buy to hold due to expected growth slowdown and current high valuation at 40.5x forward EBITDA. DOCS reported strong Q3 performance with $168.6 million revenue, 25% y/y growth, and 93.3% gross margin, driven by high pharma client demand. New ad products grew over 100% y/y, now contributing >20% of pharma revenue, showing strong underlying demand and expanding advertiser engagement.
Read More
Doximity Momentum, Big Money Support Stays Strong
Published: February 14, 2025 by: FXEmpire
Sentiment: Positive
Shares of Doximity, Inc. (DOCS) jump on business growth, investor inflows.
Read More
Doximity (DOCS) is an Incredible Growth Stock: 3 Reasons Why
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Doximity (DOCS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Read More
Why Doximity (DOCS) Might be Well Poised for a Surge
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Doximity (DOCS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Read More
Doximity (DOCS) is a Great Momentum Stock: Should You Buy?
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Doximity (DOCS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
About Doximity, Inc. (DOCS)
- IPO Date 2021-06-24
- Website https://www.doximity.com
- Industry Medical - Healthcare Information Services
- CEO Jeffrey A. Tangney
- Employees 827